Andrew I Rutherford
Overview
Explore the profile of Andrew I Rutherford including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
302
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nagra D, Bechman K, Russell M, Yang Z, Adas M, Molbanti H, et al.
Rheumatology (Oxford)
. 2024 Jun;
PMID: 38833673
Introduction: Current guidelines recommend pneumococcal vaccination in individuals who are over the age of 65 or are immunosuppressed due to a disease or treatment. The objective of this study was...
2.
Russell M, Massey J, Roddy E, Mackenna B, Bacon S, Goldacre B, et al.
Lancet Rheumatol
. 2024 Jan;
5(10):e622-e632.
PMID: 38251486
Background: Gout is the most prevalent inflammatory arthritis, yet one of the worst managed. Our objective was to assess how the COVID-19 pandemic impacted incidence and quality of care for...
3.
Russell M, Ameyaw-Kyeremeh L, DellAccio F, Lapham H, Head N, Stovin C, et al.
Rheumatology (Oxford)
. 2023 Nov;
63(8):2222-2229.
PMID: 37929968
Objectives: To evaluate a strategy designed to optimize care and increase uptake of urate-lowering therapy (ULT) during hospitalizations for gout flares. Methods: We conducted a prospective cohort study to evaluate...
4.
Russell M, Stovin C, Alveyn E, Adeyemi O, Chan C, Patel V, et al.
Ann Rheum Dis
. 2023 May;
82(8):1059-1067.
PMID: 37247942
Objectives: To estimate the association of Janus kinase inhibitors (JAKi) with the incidence of malignancy, compared with placebo, tumour necrosis factor (TNF)-α inhibitors (TNFi) and methotrexate. Methods: Systematic searches of...
5.
Russell M, Galloway J, Andrews C, Mackenna B, Goldacre B, Mehrkar A, et al.
Lancet Rheumatol
. 2022 Nov;
4(12):e853-e863.
PMID: 36447940
Background: The impact of the COVID-19 pandemic on the incidence and management of inflammatory arthritis is not understood. Routinely captured data in secure platforms, such as OpenSAFELY, offer unique opportunities...
6.
Russell M, Roddy E, Rutherford A, Ellis B, Norton S, Douiri A, et al.
Rheumatology (Oxford)
. 2022 Nov;
62(7):2426-2434.
PMID: 36355461
Objective: To investigate associations between treat-to-target urate-lowering therapy (ULT) and hospitalizations for gout. Methods: Using linked Clinical Practice Research Datalink and NHS Digital Hospital Episode Statistics data, we described the...
7.
Russell M, Rutherford A, Ellis B, Norton S, Douiri A, Gulliford M, et al.
Lancet Reg Health Eur
. 2022 Jul;
18:100416.
PMID: 35814340
Background: Following studies reporting sub-optimal gout management, European (EULAR) and British (BSR) guidelines were updated to encourage the prescription of urate-lowering therapy (ULT) with a treat-to-target approach. We investigated whether...
8.
Russell M, Nagra D, Clarke B, Balachandran S, Buazon A, Boalch A, et al.
J Rheumatol
. 2022 Mar;
49(7):725-730.
PMID: 35293331
Objective: To identify predictors of admission following emergency department (ED) attendances for gout flares and to describe barriers to optimal inpatient gout care. Methods: ED attendances and hospital admissions with...
9.
Nagra D, Russell M, Rosmini S, Sado D, Buazon A, Shafi T, et al.
Rheumatol Adv Pract
. 2021 Jun;
5(2):rkab035.
PMID: 34159291
No abstract available.
10.
Adas M, Allen V, Yates M, Bechman K, Clarke B, Russell M, et al.
Rheumatology (Oxford)
. 2021 May;
60(10):4450-4462.
PMID: 34003970
Objectives: To evaluate the safety of treatment strategies in patients with early RA. Methods: Systematic searches of MEDLINE, EMBASE and PubMed were conducted up to September 2020. Double-blind randomized controlled...